Postsurgical intra-incisional 5-fluorouracil in dogs with incompletely resected, extremity malignant spindle cell tumours: A pilot study

Veterinary and Comparative Oncology

Volumn 5, Issue 4, 2007, Pages 239-249

  Marconato, Laura ^a   Comastri, S ^a   Lorenzo, M R ^a   Abramo, F ^b   Bettini, G ^c  

^a Clinica Veterinaria L'Arca   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 fl uorouracil; Dog; Extremity; Intra incisional; Spindle cell tumour

Indexed keywords

CANIS FAMILIARIS;

EID: 65749083338     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00132.x     Document Type: Article

References (61)

1. Mauldin GN. Soft tissue sarcomas. The Veterinary Clinics of North America 1997; 27: 139-148.
2. Thrall DE and Gillette EL. Soft-tissue sarcomas. Seminars in Veterinary Medicine and Surgery (Small Animal) 1995; 10: 173-179.
3. MacEwen EG, Powers BE, Macy D and Withrow SJ. Soft tissue sarcomas. In: Small Animal Clinical Oncology, 3rd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, WB Saunders, 2001: 283-304.
4. Duda RB. Biology of mesenchymal tumours. Cancer Journal 1994; 7: 52-62.
5. Goldschmidt MH and Hendrick MJ. Tumours of the skin and soft tissues. In: Tumours in Domestic Animals, 4th edn., DJ Meuten, ed., Ames, IA, Iowa State University Press, 2002: 45-117.
6. Hendrick MJ, Mahaffey EA, Moore FM, Vos JH and Walder EJ. In: Histological Classification of Mesenchymal Tumours of Skin and Soft Tissues of Domestic Animals, 2nd series, Vol II, Washington, DC, Armed Forces Institute of Pathology, 1998.
7. Ettinger SN. Principles of treatment for soft-tissue sarcomas in the dog. Clinical Techniques in Small Animal Practice 2003; 18: 118-122.
8. Graves GM, Bjorling DE and Mahaffey E. Canine hemangiopericytoma: 23 cases (1967-1984). Journal of the American Veterinary Medical Association 1988; 192: 99-102.
9. Postorino NC, Berg RJ, Powers BE, McChesney A, Taylor R and Withrow S. Prognostic variables for canine hemangiopericytoma: 50 cases (1979-1984). Journal of the American Animal Hospital Association 1988; 24: 501-509.
10. McKnight JA, Mauldin GN, McEntee MC, Meleo KA and Patnaik AK. Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. Journal of the American Veterinary Medical Association 2000; 217: 205-210.
11. Forrest LJ, Chun R, Adams WM, Cooley AJ and Vail DM. Postoperative radiotherapy for canine soft tissue sarcoma. Journal of Veterinary Internal Medicine 2000; 14: 578-582.
12. Rassnick KM. Medical management of soft tissue sarcomas. The Veterinary Clinics of North America 2003; 33: 517-531.
13. Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA, Klausner JS, Fowler JD and McCaw D. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. Journal of the American Veterinary Medical Association 1989; 195: 1580-1583.
14. Selting KA, Powers BE, Thompson LJ, Mittleman E, Tyler JW, Lafferty MH and Withrow SJ. Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996-2004). Journal of the American Veterinary Medical Association 2005; 227: 1442-1448.
15. Ogilvie GK, Obradovich JE, Elmslie RE, Vail DM, Moore AS, Straw RC, Dickinson K, Cooper MF and Withrow SJ. Efficacy of mitoxantrone against various neoplasms in dogs. Journal of the American Veterinary Medical Association 1991; 198: 1618-1621.
16. Dernell WS, Withrow SJ, Straw RC and Lafferty MH. Adjuvant chemotherapy using cisplatin by subcutaneous administration. In Vivo 1997; 11: 345-350.
17. Payne SE, Rassnick KM, Northrup NC, Kristal O, Chretin JD, Cotter SM, Kintzer P, Frimberger AE, Morrison-Collister KE, Wood CA and Moore AS. Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin. Veterinary and Comparative Oncology 2003; 1: 171-179.
18. Gutheil JC and Finucane DM Antimetabolites. In: The Chemotherapy Source Book, MC Perry, ed., Philadelphia, Lippincott Williams & Wilkins, 2001: 214-215.
19. Ogilvie GK and Moore AS. Chemotherapy: Properties, uses, and patient management. In: Feline Oncology. A Comprehensive Guide to Compassionate Care, GK Ogilvie and AS Moore, eds., Trenton, Veterinary Learning Systems, 2001: 71.
20. Karayannopoulou M, Kaldrymidou E, Constantinidis TC and Dessiris A. Adjuvant post-operative chemotherapy in bitches with mammary cancer. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine 2001; 48: 85-96.
21. Stanclift RM and Gilson SD. Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. Journal of the American Veterinary Medical Association 2004; 225: 1412-1417.
22. Bennett PF, DeNicola DB, Bonney P, Glickman NW and Knapp DW. Canine anal sac adenocarcinomas: Clinical presentation and response to therapy. Journal of Veterinary Internal Medicine 2002; 16: 100-104.
23. Henry CJ, Brewer WG Jr, Tyler JW, Brawner WR, Henderson RA, Hankes GH and Royer N. Survival in dogs with nasal adenocarcinoma: 64 cases (1981-1995). Journal of Veterinary Internal Medicine 1998; 12: 436-439.
24. Kitchell BK, Orenberg EK, Brown DM, Hutson C, Ray K, Woods L and Luck E. Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma. European Journal of Cancer 1995; 31: 2093-2098.
25. Fry MM and Forman MA. 5-Fluorouracil toxicity with severe bone marrow suppression in a dog. Veterinary and Human Toxicology 2004; 46: 178-180.
26. Yamashita K, Yada H and Ariyoshi T. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. The Journal of Toxicological Sciences 2004; 29: 155-166.
27. Hammer AS, Carothers MA, Harris CL, O'Keefe DA, Ayl RD, Peterson JL, Shank KA and Couto CG. Unexpected neurotoxicity in dogs receiving a cyclophosphamide, dactinomycin, and 5-fluorouracil chemotherapy protocol. Journal of Veterinary Internal Medicine 1994; 8: 240-243.
28. Harvey HJ, MacEwen EG and Hayes AA. Neurotoxicosis associated with use of 5-fluorouracil in five dogs and one cat. Journal of the American Veterinary Medical Association 1977; 171: 277-278.
29. Veterinary Cooperative Oncology Group. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 194-213.
30. Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC and Withrow SJ. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). Journal of the American Veterinary Medical Association 1997; 211: 1147-1151.
31. Brehm D, Steinberg H, Haviland J and Van Winkle T. A retrospective evaluation of 51 cases of peripheral nerve sheath tumours in the dog. Journal of the American Animal Hospital Association 1995; 31: 349-359.
32. Golouh R, Bracko M and Novak J. Predictive value of proliferation-related markers, p53, and DNA ploidy for survival in patients with soft tissue spindle-cell sarcomas. Modern Pathology 1996; 9: 919-924.
33. Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y and Hirohashi S. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 2002; 95: 843-851.
34. Luong RH, Baer KE, Craft DM, Ettinger SN, Scase TJ and Bergman PJ. Prognostic significance of intratumoural microvessel density in canine soft-tissue sarcomas. Veterinary Pathology 2006; 43: 622-631.
35. Ettinger SN, Scase TJ, Oberthaler KT, Craft DM, McKnight JA, Leibman NF, Charney SC and Bergman PJ. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002). Journal of the American Veterinary Medical Association 2006; 228: 1053-1062.
36. Schoenfeld GS, Morris CG, Scarborough MT and Zlotecki RA. Adjuvant radiotherapy in the management of soft tissue sarcoma involving the distal extremities. American Journal of Clinical Oncology 2006; 29: 62-65.
37. Ferguson PC. Surgical considerations for management of distal extremity soft tissue sarcomas. Current Opinion in Oncology 2005; 17: 366-369.
38. Clarkson P and Ferguson PC. Primary multidisciplinary management of extremity soft tissue sarcomas. Current Treatment Options in Oncology 2004; 5: 451-462.
39. Sabel MS and Kraybill WG. Perfusion therapy. In: The Chemotherapy Source Book, MC Perry, ed., Philadelphia, Lippincott Williams & Wilkins, 2001: 174-184.
40. McChesney SL, Withrow SJ, Gillette EL, Powers BE and Dewhirst MW. Radiotherapy of soft tissue sarcomas in dogs. Journal of the American Veterinary Medical Association 1989; 194: 60-63.
41. Gillette SM, Dewhirst MW, Gillette EL, Thrall DE, Page RL, Powers BE, Withrow SJ, Rosner G, Wong C and Sim DA. Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: A randomized phase II study. International Journal of Hyperthermia 1992; 8: 309-320.
42. Chun R, Garrett L and MacEwen EG. Cancer chemotherapy. In: Small Animal Clinical Oncology, 3rd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, WB Saunders, 2001: 92-118.
43. Orenberg EK, Luck EE, Brown DM and Kitchell BE. Implant delivery system: intralesional delivery of chemotherapeutic agents for treatment of spontaneous skin tumours in veterinary patients. Clinical Dermatology 1992; 9: 561-568.
44. Collins JM. Pharmacologic rationale for regional drug delivery. Journal of Clinical Oncology 1984; 2: 498-504.
45. Ensminger WD and Gyves JW. Regional chemotherapy of neoplastic diseases. Pharmacology and Therapeutics 1983; 21: 277-293.
46. Théon AP, Madewell BR, Ryu J and Castro J. Concurrent irradiation and intratumoural chemotherapy with cisplatin: A pilot study in dogs with spontaneous tumours. International Journal of Radiation Oncology, Biology, Physics 1994; 29: 1027-1034.
47. Kitchell BE, Brown DM, Luck EE, Woods LL, Orenberg EK and Bloch DA. Intralesional implant for treatment of primary oral malignant melanoma in dogs. Journal of the American Veterinary Medical Association 1994; 204: 229-236.
48. Hahn KA, Richardson RC, Blevins WE, Lenz SD and Knapp DW. Intramedullary cisplatin chemotherapy: Experience in four dogs with osteosarcoma. Journal of Small Animal Practice 1996; 37: 187-192.
49. Withrow SJ, Liptak JM, Straw RC, Dernell WS, Jameson VJ, Powers BE, Johnson JL, Brekke JH and Douple EB. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Annals of Surgical Oncology 2004; 11: 705-713.
50. Lana SE, Dernell WS, LaRue SM, Lafferty MJ, Douple EB, Brekke JH and Withrow SJ. Slow release cisplatin combined with radiation for the treatment of canine nasal tumours. Veterinary Radiology and Ultrasound 1997; 38: 474-478.
51. Theon AP, Pascoe JR and Meagher DM. Perioperative intratumoural administration of cisplatin for treatment of cutaneous tumours in equidae. Journal of the American Veterinary Medical Association 1994; 205: 1170-1176.
52. Theon AP, Pascoe JR, Madigan JE, Carlson G and Metzger L. Comparison of intratumoural administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. American Journal of Veterinary Research 1997; 58: 431-436.
53. Theon AP, Pascoe JR, Galuppo LD, Fisher PE, Griffey SM and Madigan JE. Comparison of perioperative versus postoperative intratumoural administration of cisplatin for treatment of cutaneous sarcoids and squamous cell carcinomas in horses. Journal of the American Veterinary Medical Association 1999; 215: 1655-1660.
54. Yoshida K, Watarai Y, Sakai Y, Yanai T, Masegi T and Iwasaki T. The effect of intralesional bleomycin on canine acanthomatous epulis. Journal of the American Animal Hospital Association 1998; 34: 457-461.
55. Theon AP, VanVechten MK and Madewell BR. Intratumoural administration of arboplatino for treatment of squamous cell carcinomas of the nasal plane in cats. American Journal of Veterinary Research 1996; 57: 205-210.
56. De Vos JP, Burm AGO and Focker BP. Results from the treatment of advanced stage squamous cell carcinoma of the nasal planum in cats, using a combination of intralesional arboplatino and superficial radiotherapy: A pilot study. Veterinary and Comparative Oncology 2004; 2: 75-81.
57. Stewart AA, Rush B and Davis E. The efficacy of intratumoural 5-fluoruracil for the treatment of equine sarcoids. Australian Veterinary Journal 2006; 84: 101-106.
58. Kurtis B and Rosen T. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). The Journal of Dermatologic Surgery and Oncology 1980; 6: 122-127.
59. Parker CM and Hanke CW. Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. Journal of the American Academy of Dermatology 1986; 14: 770-777.
60. Laing EJ. Problems in wound healing associated with chemotherapy and radiation therapy. Problems in Veterinary Medicine 1990; 2: 433-441.
61. Bostock DE and Dye MT. Prognosis after surgical excision of canine fibrous connective tissue sarcomas. Veterinary Pathology 1980; 17: 581-588.